{{Rsnum
|rsid=1035339
|Gene=CNTN5
|Chromosome=11
|position=99995928
|Orientation=plus
|GMAF=0.3182
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CNTN5
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 50.4 | 39.8 | 9.7
| HCB | 78.8 | 19.7 | 1.5
| JPT | 80.9 | 15.5 | 3.6
| YRI | 14.5 | 47.6 | 37.9
| ASW | 22.8 | 36.8 | 40.4
| CHB | 78.8 | 19.7 | 1.5
| CHD | 78.9 | 19.3 | 1.8
| GIH | 40.0 | 48.0 | 12.0
| LWK | 21.1 | 42.2 | 36.7
| MEX | 57.1 | 35.7 | 7.1
| MKK | 20.0 | 54.2 | 25.8
| TSI | 45.5 | 39.6 | 14.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1035339
|Name_s=
|Gene_s=CNTN5
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109348
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1035339
|overall_frequency_n=49
|overall_frequency_d=128
|overall_frequency=0.382812
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}